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Background: Combination therapy with 5
alpha-reductase inhibitor (5-ARI) and
alpha-blocker can be considered as a gold standard interven-
tion for medical management of lower urinary tract symptoms
related to benign prostatic hyperplasia (LUTS/BPH). On the
other hand, 5-ARI monotherapy and in particular Finasteride
alone is currently getting focus of attention especially due to
lack of systematic reviews investigating efficacy outcomes
and/or adverse events associated.
Objectives: Aim of the present critical review was to analyze
current knowledge of clinical efficacy and incidence of adverse
events associated with 5-ARI treatment for LUTS/BPH. 
Materials and methods: A systematic review of clinical trials of
the literature of the past 20 years was performed using data-
base from PubMed, Cochrane Collaboration and Embase. A
total of 8821 patients were included in this study and inclusion
criteria for studies selection were: data from randomized clini-
cal trials (RCTs) focusing their attention on the clinical role of
Finasteride monotherapy for symptomatic BPH. Parameters of
research included prostate specific antigen (PSA), prostate vol-
ume (PV), International Prostate Symptom Score (IPPS), post-
void residual urine (PVR), voiding symptoms of IPSS (voiding
IPSS), maximum urinary flow rate (Qmax), and adverse events
(AEs). 
Results: Overall 12 original articles were included and critical-
ly evaluated. Sample sizes of patient actively treated with
finasteride varied from 13 to 1524 cases analyzed in a single
study. Follow-up after treatments ranged from 3 to 54 months.
The effect of finasteride in reducing prostate volume (PV) was
moderate (standardized mean difference (SMD) effect between
0.5 to 0.8 for all trials evaluable) while the effect on IPSS
score and Qmax was considered significant (SMD in the 0.2 to
0.5 variation range). No severe AEs and/or psychiatric disor-
ders were retrieved among the studies. Sexual health dysfunc-
tions were significantly influenced by finasteride therapy when
compared with placebo treated patients. 
Conclusions: Although significant clinical benefits of finas-
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INTRODUCTION
Benign prostatic hyperplasia (BPH) with lower urinary tract
symptoms (LUTS) is one of the most common diseases
prevalent in elderly men. Prevalence of BPH among men
in their 50s and 60s is 50% rising to 90% by the age of
80s with significant consequent impact on Quality of Live
(QoL) outcomes (1, 2). Five Alpha-Reductase Inhibitors
(5-ARI) block the conversion of testosterone to dihy-
drotestosterone, which accounts for the efficacy of its
use in the treatment of BPH/LUTS, by reducing prostate
volume (3, 4). To date, there are two types of 5-ARIs:
finasteride and dutasteride. While finasteride inhibits
only type 2 5-ARI, dutasteride inhibits both type 1 and
2, but both medications have shown similar efficacy (5).
Primary medical management of men with BPH/LUTS
include alpha-blockers and 5-ARI as standard therapy
and Serenoa repens with more limited efficacy (6-8).
Combination treatment with alpha blockers have been
demonstrated to be able to significantly decrease prostate
volume (PV), improve International Prostate Symptom
Score (IPSS), improve Qmax, decrease risk of acute urinary
retention (AUR) and operative procedures related with
BPH/LUTS better than finasteride alone. Even studies on
5-ARI monotherapy resulted, especially for finasteride,
teride monotherapy were demonstrated, the effective size of the
available reports included in the analysis is limited. Additional
head-to-head studies would be needed to re-evaluate clinical
efficacy and safety of 5-ARI in combination or not with alpha
blockers.
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in a significant improvement in all BPH related symp-
toms by long-term treatment (9, 10). However, decision
of implementing a 5-ARI monotherapy regimen of treat-
ment should be cautiously evaluated by urologists due to
recent warning data suggesting adverse clinical implica-
tions of such drugs including the events of erectile dys-
function, decreased libido, clinically significant prostate
cancer increase of incidence, gynecomastia, and anxiety
(11-15). Moreover, in their recent systematic review and
metanalysis Kim et al. (16) clearly raised the correlation
on 5-ARI administration and possible risk for suicidal
attempts and depression, showing also a considerable
number of men reporting intolerable adverse effects after
initiating finasteride therapy, and continuing to experi-
ence these effects after treatment withdrawal (10, 11).
These peripheral or secondary effects have undesirable
consequences that are collectively becoming known as
post-finasteride syndrome (17-19).
Considering the social burden of BPH significant symp-
toms on the worldwide QoL scenario in men, together
with the wide prescription/assumption of these medica-
tions, more evidence is needed in order to develop bet-
ter information for both clinicians and patients, which
could have benefits regarding shared decision making
about 5-ARI use. 
Aim of our analysis was to critically update current
knowledge specifically for the efficacy and safety profile
of finasteride 5-ARI monotherapy in men with
BPH/LUTS through a critical review of available RCTs
which have systematically implemented the use of finas-
teride as per standard of reference. In particular we ana-
lyzed the impact of finasteride monotherapy on urody-
namics variables (PV; Qmax), questionnaire score (IPSS)
and secondary outcomes (comparison with Placebo). At
the same time, we carried out a review of the drug toler-
ability and sides effects profile. 
MATERIALS AND METHODS
Evidence acquisition
We performed a systematic search
in PubMed, Embase, and Cochrane
Central Register of Controlled Trials
(CENTRAL) up to Dec 2018, with-
out language restriction, to identify
clinical trials implementing the use
of Finasteride as the only treatment
for male with BPH/LUTS and
reporting side effects related to drug
assumption compared to placebo.
The feature of related articles in
PubMed was used to identify fur-
ther papers. The reference lists of
the studies included were also
screened. Only original articles
were included and critically evaluat-
ed. We excluded case reports as
well as abstracts and reports from
meetings. An expert librarian was
involved in the design of the search
strategy and in the conduct of the
literature search. Accordingly, we searched publications
using the following primary and secondary fields: “benign
prostatic hyperplasia” and “low tract urinary symptoms”
and “5 alpha-reductase inhibitor” and “finasteride” and “5-
ARI monotherapy” and “side effects” (primary fields); “PSA
reduction” and “placebo controlled” and “randomized clini-
cal trials” (secondary fields). For all studies, we evaluat-
ed the level of evidence (LE) according to the European
Association of Urology (EAU) guidelines (Table 1) (20). 
Selection of the studies, criteria of inclusion, 
analysis of the outcomes
Entry into the analysis was restricted to data collected
from original studies, including data from BPH sympto-
matic men trials implementing finasteride as per stan-
dard of treatment compared with a placebo arm. Two
authors (FDG and GMB) independently screened the
titles and abstracts of all articles using predefined inclu-
sion criteria. The full-text articles were examined inde-
pendently by three authors (AP, FDG, and EDB) to
determine whether or not they met the inclusion criteria.
Then, two authors (FDG and BIC) extracted data from
the selected articles. Final inclusion was determined by
consensus of all investigators. Study inclusion criteria
were: 1) randomized controlled clinical trials (RCTs) with
5-ARI and placebo administration; 2) daily 5-ARI treat-
ment; 3) disease indication of BPH/LUTS; 4) types of
functional outcomes measures including at least one of
these: prostate specific antigen (PSA), prostate volume (PV),
International Prostate Symptom Score (IPPS), post-void
residual urine (PVR), voiding symptoms of IPSS (Voiding
IPSS), maximum urinary flow rate (Qmax), and adverse
events (AEs). 
To evaluate the effect of the different continuous vari-
ables analyzed, standardized mean difference (SMD) was
identified from the studies included as was recently
reported by the systematic review and metanalysis of Kim
et al. on 5-ARI monotherapy in patients with BPH (21).
In their analysis, SMDs were calculated as the difference
between the mean change in the treatment and placebo
groups divided by the pooled standard deviation (SD). 
Table 1. 
Characteristics of the studies included in the analysis.
Publication No. of patients Mean age (year)
Author Year Country Tx Placebo Tx. Placebo Finasteride F/U duration LE
dose (mg) (months)
Feneley 2000 UK, Netherland 18 9 67.5 67.5 NA 6 1b
Isotalo 2001 Finland 29 19 71 71 5 18 1b
Espana 2002 Spain 30 10 66.7 69.5 NA 9 1b
Haggstrom 2002 Sweden 13 15 NA NA 5 3 1b
Kirby 2003 Europe 239 253 63 64 5 13 1b
McConnell 2003 NA 89 128 62.6 62.5 5 54 1b
Roehrborn 2004 USA 1524 1516 64 63.9 5 48 1b
Crawford 2006 NA NA 737 - 62.5 5 54 1b
Kaplan 2006 USA 232 250 61 60.5 5 54 1b
281 274 61.8 62.4 1b
252 213 65.1 64.8 1b
Kaplan 2008 USA 768 737 62.6 62.5 5 54 1b
Kaplan 2011 USA 281 276 60.7 60.3 5 54 1b
295 288 63.9 64.1 1b
Qian 2015 China 45 42 70.1 72.3 5 6 1b
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To identify the effect of place-
bo on the continuous out-
comes, the ratio of means
(ROM), which was a measure
of relative change compared
with the baseline, was report-
ed as previously calculated by
Kim et al. (21). 
To assess the risk of bias (RoB),
all included reports were
reviewed using the Quality
Assessment of Diagnostic
Accuracy Studies (QUADAS-2)
tool for diagnostic accuracy
studies (22). The two review-
ing authors independently
assessed the methodological
quality based on sequence
generation, allocation conceal-
ment, blinding of patients and
personnel, blinding of out-
come assessors, incomplete
outcome data, selective out-
come reporting, and addition-
al sources of bias.
RESULTS
Search results
The database searches initially yielded 284 articles
(PubMed: 212; Cochrane: 8 and Embase: 64) from the past 20
years until Dec 2018. One-hundred-forty-six were exclud-
ed because they contained overlapping data or appeared in
more than one database. Of these, 64 were subsequently
removed due to duplication. On more detailed review,
additional 97 papers were excluded for the following rea-
sons: finasteride with other topics (24), other drugs and/or
combination therapy (39), animal experiment (15), and
review paper or editorials (19). 
Full-text articles were then reevaluated and critically ana-
lyzed for the remaining 41 journal references. Of these, 29
did not meet the inclusion criteria. The remaining 12 stud-
ies were considered for our critical review (Figure 1 and
Table 1). RoB assessment according to QUADAS-2 tool for
each of the individual studies is illustrated in Figure 2.
Study locations and types
Of the 12 studies included in our review, 5 were conduct-
ed in Europe, 4 in USA, 1 in China, 1 was globally dis-
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played while for one study was not available
information regarding location. All of the
studies were prospective RCTs placebo-con-
trolled implementing finasteride as reference
of standard. 
Study sample sizes, participant ages, 
and follow-up
The sample sizes of patient actively treated
with finasteride varied from 13 to 1524
cases analyzed in a single study. The total
sample size of the twelve studies was 8821
patients. The total sample size of each indi-
vidual treatment was 4096 for finasteride
4725 for placebo. Two studies did not
report participant’s age. The range of mean
age across the remaining ten studies varied
from 61 to 71 years for patients undergone
finasteride monotherapy while varied from 60 to 72 for
placebo group. In the studies, the follow-up after treat-
ments ranged from 3 to 54 months. 
Impact of finasteride monotherapy on Prostate
Volume, International Prostate Symptom Score and
Maximal Urinary Flow Rate
Regarding PV, a total of 6 articles out of the 12 included
reported extractable outcomes (23-34). The effect of
finasteride in reducing PV compared to placebo after a
median follow-up of 36 (range 6-54) months, was over-
all moderate (SMD effect between 0.5 to 0.8 for all trials
evaluable) achieving maximum outcome in the study of
Kaplan et al. (27) (-0.64; CI%95: -0.76 to -0.52). Of
note, no studies reported failure in significant decrease of
PV. Each trial effect for PV reduction resulted similar
independently from sample sizes treated demonstrating
no significant differences among studies (Feneley et al.
(23), n = 18; SMD: -0.62; CI%95: -0.80 to -0.44 Vs.
Kaplan et al. (24), n = 768; SMD: -0.63; CI%95: -0.75 to
-0.51; p = 0.782) (Table 2). 
For IPSS, a total of 5 out of 12 studies were critically
evaluated (27-31). All the studies reported a significant
improvement in the IPSS score domains after a median
follow up of 48 (range 6-54) months. The SMD effect of
finasteride for IPSS score reduction was significant (SMD
in the 0.2 to 0.5 variation range) varying from -0.19
(CI%95: -0.27 to -0.11) in the study of Quian et al. (28)
to -0.25 (CI%95: -0.33 to -0.18) in the study of Kirby et
al. (29) (Table 3). 
At the same time effect of finasteride on Qmax resulted in
significant improvement after a median follow-up of 18
(range 6 - 54) months. Seven out of 12 studies were con-
sidered (23, 24, 27-30, 32). Improvement was consid-
ered overall small (SMD in the 0.2 to 0.5 variation range)
showing minimal increase in the study of McConnel and
Crawford (30, 32) who presented identical SMD of 0.32
(CI%95: 0.24 to 0.40) compared to the study of Feneley
and Isotalo (23, 24) where a SMD of 0.36 (CI%95: 0.23
to 0.50) was retrieved (Table 4). 
Ratio of the means for PV, IPSS and Qmax, as previously
calculated by the metanalysis of Kim et al. (21), for the
efficacy of the placebo group according to our inclusion
criteria were summarized in Table 5. 
Table 4. 
Standardized mean difference (SMD) effect for Maximum
flow (Qmax) change over treatment with finasteride.
N. Pts. treated Measure of effect
Author Year Tx Placebo SMD CI%95
Feneley et al. 2000 18 9 0.36 0.23 to 0.50
Isotalo et al. 2001 29 19 0.36 0.23 to 0.50
Kirby et al. 2003 239 253 0.33 0.23 to 0.42
McConnell et al. 2003 89 128 0.32 0.24 to 0.40
Crawford et al. 2006 NA 737 0.32 0.24 to 0.40
Kaplan et al. 2011 281 276 0.30 0.22 to 0.38
295 288 0.30 0.23 to 0.37
Qian et al. 2015 45 42 0.29 0.22 to 0.36
Table 5. 
Ratio of the means for PV, IPSS and Qmax for the studies 
included in the analysis. 
Author (year) No. of samples Ratio of mean (95% CI)
PV IPSS Qmax
Feneley (2000) 9 0.82 (0.52, 1.31) 1.23 (0.85, 1.77)
Isotalo (2001) 19 0.91 (0.75, 1.11) 1.09 (0.76, 1.56)
Kirby (2003) 0.69 (0.63, 0.74) 1.12 (1.06, 1.18)
McConnell (2003) 0.76 (0.73, 0.80) 1.13 (1.10, 1.16)
Roehrborn (2004) 0.97 (0.94, 1.00)
Crawford (2006) 1.13 (1.11, 1.16)
Kaplan (2008) 249 1.34 (1.22, 1.46)
Kaplan (2008)a 214 1.12 (1.04, 1.21)
Kaplan (2008)b 112 1.20 (1.08, 1.32)
Kaplan (2008)c 161 1.21 (1.16, 1.27)
Qian (2015) 42 0.60 (0.57, 0.63) 0.36 (0.32, 0.41) 2.79 (2.36, 3.30)
Table 2. 
Standardized mean difference (SMD) effect for Prostate 
Volume (PV) change over treatment with finasteride.
N. Pts. treated Measure of effect
Author Year Tx Placebo SMD CI%95
Feneley et al. 2000 18 9 -0.62 -0.80 to -0.44
Isotalo et al. 2001 29 19 -0.63 -0.80 to -0.45
Kaplan et al. 2006 232 250 -0.61 -0.77 to -0.44
281 274 -0.60 -0.75 to -0.46
252 213 -0.60 -0.74 to -0.46
Kaplan et al. 2008 768 737 -0.63 -0.76 to -0.49
Kaplan et al. 2011 281 276 -0.63 -0.75 to -0.51
295 288 -0.64 -0.76 to -0.52
Qian et al. 2015 45 42 -0.63 -0.74 to -0.52
Table 3. 
Standardized mean difference (SMD) effect for International
Prostate Symptom Score (IPSS) change over treatment with
finasteride.
N. Pts. treated Measure of effect
Author Year Tx Placebo SMD CI%95
Kirby et al. 2003 239 253 -0.25 -0.33 to -0.18
McConnell et al. 2003 89 128 -0.24 -0.31 to 0.17
Roehrborn et al. 2004 1524 1516 -0.21 -0.31 to -0.11
Kaplan et al. 2011 281 276 -0.20 -0.29 to -0.11
295 288 -0.19 -0.28 to -0.11
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Analysis of significant adverse events rate 
for finasteride monotherapy vs. placebo
Among the twelve articles included in the analysis only
the experience of Kirby et al. and Roehrborn et al. (29,
31), clearly identified relationships between finasteride
vs. placebo in adverse events rate. Table 6 illustrates esti-
mated OR (CI%95) previously identified by Kim et al.
(23) for AEs retrieved in these studies included in our
critical review. Interestingly in their large experience
Roehrborn et al. (31) are the only that demonstrated a sig-
nificant correlation between finasteride assumption and
increased risk of developing sexual health dysfunctions:
impotence (1.83; CI%98: 1.42-2.36; p < 0.001),
decreased libido (1.97; CI%95: 1.39-2.79; p < 0.001);
ejaculatory disorder (2.81; CI%95: 1.62-4.87; p < 0.001)
and gynecomastia (3.11; CI%95: 1.78-5.45; p < 0.001),
when compared to placebo group. Of note, none of the
previous AEs was statistically found to be related in the
analysis of Kirby et al. (29) (Table 6). 
Even a comparison with other 5-ARIs (dutasteride)
demonstrated an inferior effect on male sexuality (35).
Relevantly, none of the studies included in the present
analysis found or demonstrated any significant correla-
tion between implementation of finasteride and develop-
ment of anxiety and minor/major depression syndrome. 
DISCUSSION
Androgens release and modulation profoundly regulate
homeostasis of both prostate growth and differentiation,
as well as sexual function and are associated with general
men health, including bone metabolism regulation and
cardiovascular health (36). Therefore, even if guidelines
on BPH suggest the administration of 5-ARI in patients
with symptomatic LUTS and/or prostate size greater than
30 ml, serious implications may derive from prescription
of both dutasteride and finasteride. In this field, the over-
all long-term adherence to the prescribed regimen (alpha
blockers or 5-ARI or combination) has been demonstrat-
ed to be generally low, but it is even more limited in
patients under 5-ARI, probably due to the incidence of
AEs (37). Significant higher events of heart failure com-
pared to placebo group have been indeed described in the
study of Andriole et al in 2010 looking at correlation
between 5-ARI and risk of prostate cancer development
(38). Moreover, many observational studies and the
recently published metanalysis by Kim et al. have shown
increased incidence of possible risk for suicidal attempts
and minor/major depression events (16, 39). 
On the other hand, the indication of treatment with 5-
ARI seems clear and confirmed from many available trials
and review analysis. Goals of finasteride treatment are
represented by preventing over the years the exacerbation
of BPH and urinary retention and therefore its routinely
use demonstrated to be a reliable tool able to impact clin-
ical urinary outcomes and at the same time to improve
perioperative results of patients candidate for endouro-
logical procedures such as TURP/simple prostatectomy
and others. In 2015 Busetto GM et al. (40) in their obser-
vational study demonstrated how preoperative (TURP) 5-
ARI treatment could have improved estimated blood loss
and histopathological findings of prostate vascularity by
impacting on vascular endothelial growth factor (VEGF)
immunoreactivity and micro-vessel density (MVD) modu-
lation specifically in large prostates (> 50 ml). 
From all these observations, necessity arises to periodi-
cally update data regarding the worldwide impact of
these medications and the real clinical benefit for men
suffering from BPH. Moreover, new formulations of
finasteride drug have been yearly introduced in the phar-
macy market in the last few years demonstrating the con-
tinuous interest in the field of BPH medical therapy. 
We on purpose decided to restrict the field of research of
the present review on a smaller window (20 years) when
compared to previously published reviews articles in
order to photograph the current changes in literature.
Finasteride is indeed for sure the 5-ARI medication
which has been more prescribed and on which are pres-
ent most of the available trials in literature antecedent to
year 2000. The first two RCT using finasteride notewor-
thy are dated 1992 when Beisland et al. (41) and Gormley
et al. (42) respectively published their analysis on
European Urology and New England Journal of Medicine,
demonstrating, especially the last one, a significant effect
despite the short term follow-up on voiding IPSS scores
(OR: 0.88; CI%95: 0.80 to 0.97). 
Therefore, our review has been based on the results
recently provided by the metanalysis published by Kim et
al. (21), but with different criteria of inclusion and a
shorter time frame of literature review focusing only on
finasteride monotherapy. The level of evidence raised by
the 12 included RCT articles was overall good (LE: ≥ 2a)
with homogeneous distribution in terms of sample size,
balanced treatment groups and placebo arms and both
urinary and AEs outcomes investigated. Finasteride
monotherapy demonstrated to be able to positively and
significantly impact all the urinary variables (PV, IPSS,
Qmax) in all the studies included, showing a SMD effect
ranging between small to moderate effect on the ana-
lyzed variable. Severe AEs were not reported, and the
main issue was again the impact of the drug on sexual
health life. Only Roehrborn et al. RCT (31) reported an
association between finasteride and sexuality (31).
Finasteride sexual side effects profile is better when com-
pared with dutasteride (35). Even if our results did not
identify any correlation among the studies included and
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Table 6. 
OR of the Adverse events (AEs) among studies enrolled 
for finasteride treatment compared to placebo.
Complication Effect size
OR (95% CI) p-value
Decreased libido
Kirby (2003) 1.83 (0.62-5.4) 0.271
Roehrborn (2004) 1.97 (1.39-2.79) < 0.001
Ejaculatory disorder
Kirby (2003) 1.53 (0.44-5.35) 0.507
Roehrbn (2004) 2.81 (1.62-4.87) < 0.001
Impotence 1.68 (1.3-2.17) < 0.001
Kirby (2003) 1.47 (0.64-3.38) 0.363
Roehrborn (2004) 1.83 (1.42-2.36) < 0.001
Postural hypotension 1.18 (0.27-5.12) 0.821
Kirby (2003) 0.51 (0.09-2.76) 0.434
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the risk of psychiatric AEs, the metanalysis of Kim et al.
(16) published in 2019, investigating the risk of depres-
sion with 5-ARI, showed a not high risk but however a
relevant distribution of these events which for their clin-
ical importance needs validation by further studies. 
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